WO2023122532A3 - Compositions and methods for engineering treg cells for treatment of diabetes - Google Patents
Compositions and methods for engineering treg cells for treatment of diabetes Download PDFInfo
- Publication number
- WO2023122532A3 WO2023122532A3 PCT/US2022/081929 US2022081929W WO2023122532A3 WO 2023122532 A3 WO2023122532 A3 WO 2023122532A3 US 2022081929 W US2022081929 W US 2022081929W WO 2023122532 A3 WO2023122532 A3 WO 2023122532A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- edited
- engineering
- treg cells
- dual
- locus
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 102100027581 Forkhead box protein P3 Human genes 0.000 abstract 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL313581A IL313581A (en) | 2021-12-21 | 2022-12-19 | Compositions and methods for engineering treg cells for treatment of diabetes |
CA3242057A CA3242057A1 (en) | 2021-12-21 | 2022-12-19 | Compositions and methods for engineering treg cells for treatment of diabetes |
AU2022420487A AU2022420487A1 (en) | 2021-12-21 | 2022-12-19 | Compositions and methods for engineering treg cells for treatment of diabetes |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163292125P | 2021-12-21 | 2021-12-21 | |
US63/292,125 | 2021-12-21 | ||
US202263363918P | 2022-04-29 | 2022-04-29 | |
US63/363,918 | 2022-04-29 | ||
US202263364285P | 2022-05-06 | 2022-05-06 | |
US63/364,285 | 2022-05-06 | ||
US202263378928P | 2022-10-10 | 2022-10-10 | |
US63/378,928 | 2022-10-10 | ||
US202263384830P | 2022-11-23 | 2022-11-23 | |
US63/384,830 | 2022-11-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023122532A2 WO2023122532A2 (en) | 2023-06-29 |
WO2023122532A3 true WO2023122532A3 (en) | 2023-08-03 |
Family
ID=86903699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/081929 WO2023122532A2 (en) | 2021-12-21 | 2022-12-19 | Compositions and methods for engineering treg cells for treatment of diabetes |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2022420487A1 (en) |
CA (1) | CA3242057A1 (en) |
IL (1) | IL313581A (en) |
WO (1) | WO2023122532A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110151447A1 (en) * | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
WO2020264039A1 (en) * | 2019-06-27 | 2020-12-30 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Artificial antigen-specific immunoregulatory t (airt) cells |
-
2022
- 2022-12-19 AU AU2022420487A patent/AU2022420487A1/en active Pending
- 2022-12-19 IL IL313581A patent/IL313581A/en unknown
- 2022-12-19 CA CA3242057A patent/CA3242057A1/en active Pending
- 2022-12-19 WO PCT/US2022/081929 patent/WO2023122532A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110151447A1 (en) * | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
WO2020264039A1 (en) * | 2019-06-27 | 2020-12-30 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Artificial antigen-specific immunoregulatory t (airt) cells |
Also Published As
Publication number | Publication date |
---|---|
AU2022420487A1 (en) | 2024-07-04 |
CA3242057A1 (en) | 2023-06-29 |
IL313581A (en) | 2024-08-01 |
WO2023122532A2 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000553A (en) | Immune effector cell engineering and use thereof. | |
EP4249074A3 (en) | Genomic engineering of pluripotent cells | |
BR112022021676A2 (en) | IN VITRO CELL DELIVERY METHODS | |
MX2021008920A (en) | A method of gene editing. | |
MX2021003457A (en) | Compositions and methods for lactate dehydrogenase (ldha) gene editing. | |
WO2020082042A3 (en) | Compositions and methods for transgene expression from an albumin locus | |
WO2018097540A3 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
AU2018256348A1 (en) | A platform for T lymphocyte genome engineering and in vivo high-throughput screening thereof | |
WO2007028041A3 (en) | Loading of cells with antigens by electroporation | |
MX2022015863A (en) | Combining ipsc-derived effector cell types for immunotherapy use. | |
WO2004074451A3 (en) | Loading of cells with antigens by electroporation | |
EP4063487A4 (en) | Amplification and differentiation method for pancreatic cells and use thereof | |
EP3984596A4 (en) | Cell population including mesenchymal cells, pharmaceutical composition including same, and method for producing same | |
WO2023122532A3 (en) | Compositions and methods for engineering treg cells for treatment of diabetes | |
WO2022016166A3 (en) | Differentiation of trophectoderm lineage cells from pluripotent stem cells | |
MX2023011927A (en) | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells. | |
WO2023070031A3 (en) | Discovery and engineering of integrases for high-efficiency gene integration | |
EP4142754A4 (en) | Methods for generating thymic cells in vitro | |
EP4065138A4 (en) | Large-scale combined car transduction and crispr gene editing of msc cells | |
MX2021012649A (en) | Cell culture medium for eukaryotic cells. | |
WO2022272292A3 (en) | Engineered cells for therapy | |
WO2023122755A3 (en) | Flow cells and methods | |
WO2022170193A3 (en) | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy | |
CA3141051A1 (en) | Catalysed membrane | |
MX2023007480A (en) | Sialyltransferases for the production of 6'-sialyllactose. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22912622 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 313581 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022420487 Country of ref document: AU Ref document number: AU2022420487 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3242057 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22912622 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022912622 Country of ref document: EP Effective date: 20240722 |